Literature DB >> 11561795

Inhibition of lens epithelial cell adhesion by the calcium antagonist Mibefradil correlates with impaired integrin distribution and organization of the cytoskeleton.

R Beck1, B Nebe, R Guthoff, J Rychly.   

Abstract

BACKGROUND: Posterior capsule opacification is the most common complication of primary cataract surgery and is caused by migration and proliferation of residual lens epithelial cells onto the posterior capsule. Interfering with the mechanisms involved in cell adhesion is a suitable approach to prevent posterior capsule opacification.
METHODS: Mibefradil, a T-type calcium-channel blocker, was used to examine the influence on adhesion-mediating mechanisms in human lens epithelial cells derived from cataract surgery. Adhesion was evaluated by light microscopy on the anterior capsules. Expression of integrin receptors was studied by flow cytometry. The influence on the distribution of integrin receptors on the cell surface and the organization of the cytoskeleton was examined by immunofluorescence using a confocal microscope.
RESULTS: The calcium-channel blocker Mibefradil inhibited cell adhesion on the anterior capsule wall at concentrations between 10 and 100 pNM. The cells expressed the integrin subunits beta1 and alpha3. Mibefradil distinctly impaired the distribution of these integrins on the cell surface in culture. The cells express the cytoskeletal components actin, vimentin and, very weakly, cytokeratin. The structural organization of the actin filaments and vimentin was strongly disrupted with pronounced fragmentation of the actin filaments in the presence of the calcium-channel blocker.
CONCLUSION: The results suggest that the inhibition of cell adhesion by the calcium-channel blocker Mibefradil involves the impairment of integrin-mediated mechanisms. The use of this calcium antagonist appears to be a suitable therapeutic approach to prevent posterior capsule opacification.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561795     DOI: 10.1007/s004170100303

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  7 in total

1.  Effect of extracellular matrix on proliferation and differentiation of porcine lens epithelial cells.

Authors:  Yvonne de Jong-Hesse; Juergen Kampmeier; Gerhard K Lang; Gabriele E Lang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-02-09       Impact factor: 3.117

2.  Adherence and viability of porcine lens epithelial cells on three different IOL materials in vitro.

Authors:  Yvonne Hesse; Jürgen Kampmeier; Gerhard K Lang; Alicia Baldysiak-Figiel; Gabriele E Lang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-08-23       Impact factor: 3.117

3.  Induction of apoptosis by the calcium antagonist mibefradil correlates with depolarization of the membrane potential and decreased integrin expression in human lens epithelial cells.

Authors:  Barbara Nebe; Friederike Kunz; Annelie Peters; Joachim Rychly; Thomas Noack; Ria Beck
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-04-07       Impact factor: 3.117

4.  Ischemia-induced apoptosis of intestinal epithelial cells correlates with altered integrin distribution and disassembly of F-actin triggered by calcium overload.

Authors:  Zhenyi Jia; Qian Chen; Huanlong Qin
Journal:  J Biomed Biotechnol       Date:  2012-05-30

5.  Killing two birds with one stone: dual blockade of integrin and FGF signaling through targeting syndecan-4 in postoperative capsular opacification.

Authors:  Yingyan Qin; Yi Zhu; Furong Luo; Chuan Chen; Xiaoyun Chen; Mingxing Wu
Journal:  Cell Death Dis       Date:  2017-07-13       Impact factor: 8.469

6.  Prevention of lens epithelial cell growth in vitro using mibefradil-containing PLGA micro particles.

Authors:  Arne Weidmann; Sabine Kwittner; Ria Beck; Joachim Teller; Ludwig Jonas; J Barbara Nebe
Journal:  Open Ophthalmol J       Date:  2008-06-12

7.  TGFbeta1 signaling via alphaVbeta6 integrin.

Authors:  Martin P Kracklauer; Christian Schmidt; Guido M Sclabas
Journal:  Mol Cancer       Date:  2003-08-07       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.